Amino Acid-based peritoneal dialysis solutions for malnutrition: new perspectives.
Hoey Lan Tjiong, Roel Swart, Jacobus W van den Berg...
https://pubmed.ncbi.nlm.nih.gov/19602603/Actively Recruiting
Led by Chengdu Qingshan Likang Pharmaceutical Co., Ltd · Updated on 2024-12-30
400
Participants Needed
21
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effectiveness of an amino acid 15 peritoneal dialysis solution in patients undergoing peritoneal dialysis who have malnutrition. This Phase IV, multicenter, randomized, parallel controlled study focuses on patients receiving continuous ambulatory peritoneal dialysis CAPD maintenance treatment. The goal is to compare the amino acid solution with conventional glucose peritoneal dialysis solution in this population with End Stage Renal Disease ESRD. Participants are randomly assigned to one of two groups an experimental group receiving one bag of amino acid 15 peritoneal dialysate 2 liters each morning followed by conventional glucose dialysate, and a control group receiving conventional glucose peritoneal dialysis solution including 1.5% glucose dialysate 2 liters once daily. The number of dialysate exchanges, fluid volume, and dwell times are adjusted based on individual patient needs. The treatment period lasts 90 days, during which safety and effectiveness are monitored. Participants undergo screening, baseline assessments, and regular monitoring throughout the study. Blood tests and biochemical markers are checked at 30, 60, and 90 days, including serum albumin, transferrin, and prealbumin levels. Nutritional and physical assessments such as subjective global assessment SGA, arm muscle circumference AMC, mid-arm muscle circumference MAMC, body mass index BMI, and protein nitrogen appearance nPNA are evaluated at 90 days. The study also tracks total daily ultrafiltration volume and records all adverse events. The entire participation timeline includes a screening period before treatment and close observation during the 90-day treatment phase.
CONDITIONS
Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.
Q
Qian Deng
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Up to 3 days
Participants who pass screening are re-verified for eligibility and baseline measurements are collected before treatment starts.
1 baseline visit (in-person)
Duration - 90 days
Participants receive daily peritoneal dialysis treatment with either amino acid (15) peritoneal dialysis solution or glucose peritoneal dialysis solution for nutritional support and dialysis.
Daily treatment with monitoring visits on Day 30, Day 60, and Day 90
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Hoey Lan Tjiong, Roel Swart, Jacobus W van den Berg...
https://pubmed.ncbi.nlm.nih.gov/19602603/Luu Thi My Thuc, Nguyen Quang Dung, Vu Ngoc Ha...
https://pubmed.ncbi.nlm.nih.gov/31464251/J D Kopple, D Bernard, J Messana...
https://pubmed.ncbi.nlm.nih.gov/7783413/Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Lead Sponsor